公开(公告)号：US20240343731A1

公开(公告)日：2024-10-17

申请号：US18437153

申请日：2024-02-08

申请人： BIOMEA FUSION, INC.

发明人： Priyanka SOMANATH ,  Daniel LU ,  Taisei KINOSHITA ,  Brian LAW ,  Thomas BUTLER ,  James T. PALMER ,  Nan-Horng LIN ,  Heow Meng TAN ,  Angelina Sau Man WONG ,  Siyi JIANG ,  Hongyan HE

IPC分类号： C07D487/04 ,  A61K9/00 ,  A61K9/48 ,  A61P35/00 ,  A61P35/02

CPC分类号： C07D487/04 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61P35/00 ,  A61P35/02 ,  C07B2200/13

摘要： Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.